Main Article Content

Abstract

RÉSUMÉ
L’arrivée des anticoagulants oraux directs en milieu sub-saharien a révolutionné la prise en charge des patients en fibrillation atriale non valvulaire. Cependant, non dénués de complications, les hémorragies intracrâniennes ont l’une des complications les plus redoutées. Les hématomes sous duraux aigus d’origine iatrogène ne sont pas décrits dans la littérature sub-saharienne, aussi très peu de données sont disponibles. Nous rapportons les cas deux patientes ayant présenté des hématomes sous duraux sous rivaroxaban.


ABSTRACT
The arrival of direct oral anticoagulants (AODs) in sub-Saharan settings has revolutionized the management of patients with non-valvular atrial fibrillation. However, not without complications, intracranial hemorrhages (HINT) are one of the most feared complications. Acute subdural hematomas (HSD) of iatrogenic origin are not described in the sub-Saharan literature, so very few data are available. We report two cases of patients followed for rivaroxaban induced acute sub dural hematomas.

Article Details

How to Cite
Amalia N, O., Oumarou, H., Boombhi, J., Djientcheu, V. de P., Menanga, A. P. ., & Kingue, S. . (2021). Hématome Sous-Dural Aigu sous Rivaroxaban : A Propos de Deux Cas: Rivaroxaban induced acute sub-dural hematoma : A report of 2 cases. HEALTH SCIENCES AND DISEASE, 23(1), 4. Retrieved from https://www.hsd-fmsb.org/index.php/hsd/article/view/3231

References

  1. Rosand J, Eckman MH, Knudsen KA, et al. (2004) The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 164: 880-4.
  2. Oden A, Fahlen M (2002) Oral anticoagulation and risk of death: a medical record linkage study. BMJ 325: 1073-5.
  3. Connolly SJ, Ezekowitz MD, Yusuf S et al. ; the RE-LY stering commetee and investigator. Dabigatran versus warfarin in patients with atrial fibrillation. Engl J Med, 2009, 361:1139-1151.
  4. Hermans C. Le Rivaroxaban (Xarelto®): état des lieux des nouvelles données et perspectives thérapeutiques. Louvain Med 2020 octobre ; 139 (08) : 446-459.
  5. A. Godier, A.-C. Martin. Les antidotes des anticoagulants oraux directs. JMV-Journal de Médecine Vasculaire 2017 ; 42 (02) : 77.
  6. Fofana AS, Sy S, Coulibaly M et al. Hematome sous-dural aigu spontane du patient en hemodialyse chronique : a propos de un cas et revue de la litterature. Mali medical 2020 ; 35(2) :52-55.
  7. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005;61: 873–80.
  8. Derlon V, Corbonnois G, Martin M, Toussaint-Hacquart, Audibert G. Hémorragies cérébrales et nouveaux anticoagulants. Ann Fr Anesth Reanim. 2014. 4413 (9): 495-553
  9. Patel MR, Mahaffey KW et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365: 883–91.
  10. Hori M, Matsumoto M, Tanahashi N et al. Rivaroxaban vs warfarin in Japanese patients with atrial fibrillation. Circ J 2012;76: 2104–11.
  11. Bruins Slot K, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev 2013 : 8.
  12. Michel P, Quenon JL, Djihoud A, Tricaud-Vialle S, de Sarasqueta AM. French national survey of inpatient adverse events prospectively assessed with ward staff. Qual Saf Health Care. 2007;16(5): 369 77.
  13. Palareti G, Leali N, Coccheri S et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). The Lancet. 1996;348(9025):423 8.
  14. Hemphill JC III, Bonovich DC, Besmertis L et al. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke 2001 ; 32 : 891-7.
  15. Murai Y, Ikeda Y, Teramoto A et al. Contrast extravasation on CT angiography predicts hematoma expansion in intracerebral hemorrhage. Neurology 2007 ; 69 : 617.
  16. Kidwell CS, Chalela JA, Saver JL et al. Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA 2004 ; 292 : 1823-30.
  17. Steiner T, Diringer MN, Schneider D et al. Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII. Neurosurgery 2006 ; 59 : 767-73.
  18. Ohwaki K, Yano E, Nagashima H, et al. Blood pressure management in acute intracerebral hemorrhage: relationship between elevated blood pressure and hematoma enlargement. Stroke 2004 ; 35 : 1364-7.
  19. Moon JS, Janjua N, Ahmed S et al. Prehospital neurologic deterioration in patients with intracerebral hemorrhage. Crit Care Med 2008 ; 36 : 172-5.
  20. Anderson CS, Huang Y, Wang JG et al. Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT): a randomised pilot trial. Lancet Neurol 2008 ; 7 : 391–99.
  21. Qureshi AI, Tariq N, Divani AA et al. Antihypertensive treatment of acute cerebral hemorrhage. Crit Care Med 2010 ; 38 : 637–48.
  22. Idsalem N, Volet décompressif de l’hématome sous dural aigu, à propos de 76 cas, thèse méd, 13M223, méd, 2004, Faculté de Médecine et de Pharmacie, Casablanca, Maroc.
  23. Gebel JM, Sila CA, Sloan MA et al. Comparison of the ABC/2 estimation technique to computer-assisted volumetric analysis of intraparenchymal and subdural hematomas
  24. complicating the GUSTO-1 trial. Stroke 1998 ; 29 : 1799-1801.

Most read articles by the same author(s)

1 2 3 > >>